Publication:
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.

Simple item page
dc.contributor.authorMaerevoet, Marie
dc.contributor.authorZijlstra, Josee M
dc.contributor.authorFollows, George
dc.contributor.authorCasasnovas, Rene-Olivier
dc.contributor.authorVermaat, J S P
dc.contributor.authorKalakonda, Nagesh
dc.contributor.authorGoy, Andre
dc.contributor.authorChoquet, Sylvain
dc.contributor.authorVan Den Neste, Eric
dc.contributor.authorHill, Brian
dc.contributor.authorThieblemont, Catherine
dc.contributor.authorCavallo, Federica
dc.contributor.authorDe la Cruz, Fatima
dc.contributor.authorKuruvilla, John
dc.contributor.authorHamad, Nada
dc.contributor.authorJaeger, Ulrich
dc.contributor.authorCaimi, Paolo
dc.contributor.authorGurion, Ronit
dc.contributor.authorWarzocha, Krzysztof
dc.contributor.authorBakhshi, Sameer
dc.contributor.authorSancho, Juan-Manuel
dc.contributor.authorSchuster, Michael
dc.contributor.authorEgyed, Miklos
dc.contributor.authorOffner, Fritz
dc.contributor.authorVassilakopoulos, Theodoros P
dc.contributor.authorSamal, Priyanka
dc.contributor.authorKu, Matthew
dc.contributor.authorMa, Xiwen
dc.contributor.authorCorona, Kelly
dc.contributor.authorChamoun, Kamal
dc.contributor.authorShah, Jatin
dc.contributor.authorShacham, Sharon
dc.contributor.authorKauffman, Michael G
dc.contributor.authorCanales, Miguel
dc.date.accessioned2023-02-09T11:43:27Z
dc.date.available2023-02-09T11:43:27Z
dc.date.issued2021-07-16
dc.description.abstractPatients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of 
dc.identifier.doi10.1186/s13045-021-01122-1
dc.identifier.essn1756-8722
dc.identifier.pmcPMC8283921
dc.identifier.pmid34271963
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283921/pdf
dc.identifier.unpaywallURLhttps://jhoonline.biomedcentral.com/counter/pdf/10.1186/s13045-021-01122-1
dc.identifier.urihttp://hdl.handle.net/10668/18206
dc.issue.number1
dc.journal.titleJournal of hematology & oncology
dc.journal.titleabbreviationJ Hematol Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number111
dc.pubmedtypeClinical Trial
dc.pubmedtypeLetter
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectDLBCL
dc.subjectExportin-1
dc.subjectSINE compounds
dc.subjectSelinexor
dc.subject.meshAge Factors
dc.subject.meshAged
dc.subject.meshHumans
dc.subject.meshHydrazines
dc.subject.meshLymphoma, Large B-Cell, Diffuse
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshSurvival Analysis
dc.subject.meshTreatment Outcome
dc.subject.meshTriazoles
dc.titleSurvival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number14
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC8283921.pdf
Size:
1009.75 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía